Want to see HK:2367 full AI Analyst Report?
Giant Biogene Holding Co. Ltd. (2367) Ratios
Giant Biogene Holding Co. Ltd. Ratios
HK:2367's free cash flow for Q2 2026 was $813.32M. For the 2026 fiscal year, HK:2367's free cash flow was decreased by $-94.20M and operating cash flow was $907.51M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 11.27 | 7.66 | 7.79 | 9.03 | 1.09 |
| Quick Ratio | 10.78 | 7.29 | 7.42 | 8.38 | 1.07 |
| Cash Ratio | 7.88 | 4.82 | 4.72 | 4.74 | 1.04 |
| Solvency Ratio | 2.18 | 2.28 | 2.47 | 3.42 | 0.12 |
| Operating Cash Flow Ratio | 2.37 | 2.44 | 3.10 | 3.32 | 0.10 |
| Short-Term Operating Cash Flow Coverage | 295.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 8.11B | $ 5.48B | $ 3.53B | $ 2.24B | $ 579.92M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.13 | 1.14 | 1.11 | 7.75 |
| Debt Service Coverage Ratio | 262.51 | 8006.40 | 13236.51 | 49011.19 | 0.00 |
| Interest Coverage Ratio | 7022.46 | 9659.55 | 14864.94 | 53959.05 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | -2.86 | -1.74 | -1.41 | -1.10 | -7.61 |
| Profitability Margins | |||||
| Gross Profit Margin | 80.34% | 82.09% | 83.63% | 84.39% | 87.24% |
| EBIT Margin | 38.43% | 41.13% | 49.52% | 49.81% | 58.65% |
| EBITDA Margin | 39.92% | 41.70% | 50.49% | 50.98% | 60.14% |
| Operating Profit Margin | 38.43% | 41.68% | 47.24% | 47.92% | 58.91% |
| Pretax Profit Margin | 42.59% | 44.37% | 49.52% | 49.81% | 62.67% |
| Net Profit Margin | 34.70% | 37.23% | 41.19% | 42.38% | 53.34% |
| Continuous Operations Profit Margin | 34.70% | 37.22% | 41.09% | 42.36% | 53.34% |
| Net Income Per EBT | 81.47% | 83.91% | 83.19% | 85.08% | 85.12% |
| EBT Per EBIT | 110.82% | 106.46% | 104.82% | 103.94% | 106.38% |
| Return on Assets (ROA) | 17.65% | 25.66% | 29.19% | 31.93% | 10.51% |
| Return on Equity (ROE) | 19.31% | 29.01% | 33.28% | 35.36% | 81.44% |
| Return on Capital Employed (ROCE) | 21.11% | 32.06% | 37.48% | 39.66% | 88.35% |
| Return on Invested Capital (ROIC) | 17.19% | 26.87% | 31.09% | 33.72% | 75.20% |
| Return on Tangible Assets | 17.66% | 25.68% | 29.24% | 32.00% | 10.52% |
| Earnings Yield | 6.06% | 4.40% | 4.59% | 3.46% | 3.91% |
| Efficiency Ratios | |||||
| Receivables Turnover | 27.33 | 34.48 | 47.15 | 34.06 | 22.30 |
| Payables Turnover | 5.46 | 3.46 | 4.33 | 6.76 | 8.39 |
| Inventory Turnover | 2.77 | 3.19 | 2.88 | 2.01 | 2.22 |
| Fixed Asset Turnover | 3.95 | 4.70 | 4.95 | 4.29 | 4.65 |
| Asset Turnover | 0.51 | 0.69 | 0.71 | 0.75 | 0.20 |
| Working Capital Turnover Ratio | 0.80 | 1.21 | 1.20 | 1.66 | 4.38 |
| Cash Conversion Cycle | 78.13 | 19.46 | 50.33 | 138.49 | 137.54 |
| Days of Sales Outstanding | 13.36 | 10.59 | 7.74 | 10.72 | 16.37 |
| Days of Inventory Outstanding | 131.59 | 114.37 | 126.79 | 181.80 | 164.67 |
| Days of Payables Outstanding | 66.82 | 105.50 | 84.20 | 54.03 | 43.49 |
| Operating Cycle | 144.95 | 124.96 | 134.54 | 192.52 | 181.04 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.79 | 2.04 | 1.68 | 0.95 | 0.71 |
| Free Cash Flow Per Share | 1.40 | 1.79 | 1.45 | 0.80 | 0.60 |
| Dividend Paid and CapEx Coverage Ratio | 1.14 | 1.77 | 7.21 | 1.79 | 0.26 |
| Capital Expenditure Coverage Ratio | 4.55 | 8.27 | 7.21 | 6.08 | 6.23 |
| Operating Cash Flow Coverage Ratio | 195.80 | 304.20 | 603.68 | 360.26 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.34 | 0.37 | 0.47 | 0.39 | 0.45 |
| Free Cash Flow Yield | 4.68% | 3.82% | 4.48% | 2.69% | 2.74% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 16.33 | 22.75 | 21.80 | 28.90 | 25.60 |
| Price-to-Sales (P/S) Ratio | 5.73 | 8.47 | 8.98 | 12.25 | 13.65 |
| Price-to-Book (P/B) Ratio | 3.19 | 6.60 | 7.25 | 10.22 | 20.85 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 21.35 | 26.15 | 22.30 | 37.20 | 36.47 |
| Price-to-Operating Cash Flow Ratio | 16.66 | 22.99 | 19.21 | 31.08 | 30.61 |
| Price-to-Earnings Growth (PEG) Ratio | -1.27 | 0.56 | 0.43 | 1.62 | 21.24 |
| Enterprise Value Multiple | 11.50 | 18.57 | 16.38 | 22.92 | 15.10 |
| Enterprise Value | 25.32B | 42.90B | 29.14B | 27.63B | 14.09B |
| EV to EBITDA | 11.50 | 18.57 | 16.38 | 22.92 | 15.10 |
| EV to Sales | 4.59 | 7.74 | 8.27 | 11.68 | 9.08 |
| EV to Free Cash Flow | 17.10 | 23.91 | 20.54 | 35.49 | 24.25 |
| EV to Operating Cash Flow | 13.34 | 21.02 | 17.69 | 29.66 | 20.35 |
| Tangible Book Value Per Share | 9.38 | 7.11 | 4.45 | 2.90 | 1.04 |
| Shareholders’ Equity Per Share | 9.37 | 7.10 | 4.45 | 2.90 | 1.04 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.19 | 0.16 | 0.17 | 0.15 | 0.15 |
| Revenue Per Share | 5.22 | 5.53 | 3.59 | 2.42 | 1.59 |
| Net Income Per Share | 1.81 | 2.06 | 1.48 | 1.03 | 0.85 |
| Tax Burden | 0.81 | 0.84 | 0.83 | 0.85 | 0.85 |
| Interest Burden | 1.11 | 1.08 | 1.00 | 1.00 | 1.07 |
| Research & Development to Revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| SG&A to Revenue | 0.40 | 0.39 | 0.03 | 0.05 | 0.01 |
| Stock-Based Compensation to Revenue | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 |
| Income Quality | 1.02 | 0.83 | 0.94 | 0.79 | 0.71 |
Currency in CNY
